Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Cash & Current Investments (2016 - 2025)

Arcadia Biosciences' Cash & Current Investments history spans 12 years, with the latest figure at $4.6 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 7.57% year-over-year to $4.6 million; the TTM value through Dec 2025 reached $4.6 million, up 7.57%, while the annual FY2025 figure was $4.6 million, 7.57% up from the prior year.
  • Cash & Current Investments reached $4.6 million in Q4 2025 per RKDA's latest filing, down from $5.9 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $51.9 million in Q1 2021 to a low of $3.2 million in Q1 2025.
  • Average Cash & Current Investments over 5 years is $18.2 million, with a median of $17.1 million recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: skyrocketed 340.23% in 2021, then tumbled 63.56% in 2024.
  • A 5-year view of Cash & Current Investments shows it stood at $28.7 million in 2021, then fell by 28.03% to $20.6 million in 2022, then tumbled by 43.61% to $11.6 million in 2023, then crashed by 63.56% to $4.2 million in 2024, then grew by 7.57% to $4.6 million in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Cash & Current Investments are $4.6 million (Q4 2025), $5.9 million (Q3 2025), and $4.4 million (Q2 2025).